Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. - Investor Relations & Filings

Listed
Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 457 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN · 2 venues

Key figures FY2026

Period ended 2026-03-31 · INR
Headline annual figures for Lincoln Pharmaceuticals ltd., fiscal year 2026, reported in INR, with the source filing for each figure.
Total Revenues INR 6.71B per the Earnings Release filed 2026-05-28
Net Income INR 878.94M per the Earnings Release filed 2026-05-28
Total Assets INR 8.90B per the Earnings Release filed 2026-05-28
Total Equity INR 7.58B per the Earnings Release filed 2026-05-28
Cash from Ops INR 1.06B per the Earnings Release filed 2026-05-28

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund)Rules, 2016 and amendments thereof.
Regulatory Filings Classification · 95% confidence The document is a letter from Lincoln Pharmaceuticals Ltd. addressed to stock exchanges regarding a newspaper advertisement for the transfer of equity shares to the Investor Education Protection Fund Authority (IEPF Authority). It references compliance with the Companies Act, 2013 and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and mentions a notice published in the newspaper inviting shareholders to claim unclaimed dividends before shares are transferred to the IEPF Authority. The document is essentially an announcement of a regulatory compliance action and a published notice, not a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. The document length is about 7,316 characters, which is relatively short and consistent with an announcement. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication.
2026-05-08 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Ltd. providing clarification regarding previously submitted quarterly financial results for the quarter ended September 2025. It explains why the standalone and consolidated profit and loss figures are identical due to no transactions in the subsidiary. The document is short (2072 characters) and serves as a clarification or regulatory communication rather than the financial report itself. It does not contain actual financial statements or substantive financial data but rather addresses a regulatory observation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2026-04-08 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a disclosure filed by the promoter group of Lincoln Pharmaceuticals Limited under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It declares that no encumbrance of shares was made during the financial year 2025-2026. This type of regulatory disclosure regarding shareholding and encumbrance status does not fit into specific categories like 'Major Shareholding Notification' (which usually involves crossing thresholds) or 'Director's Dealing'. As it is a standard regulatory compliance filing required by SEBI, it falls under the 'Regulatory Filings' (RNS) category.
2026-04-08 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a disclosure filed by a promoter regarding shareholding and encumbrance status under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. While it mentions 'Takeover' in the title, it is specifically a notification of shareholding and encumbrance status by a major shareholder/promoter group, which falls under the category of Major Shareholding Notification (MRQ) as it pertains to reporting significant ownership and encumbrance status to the exchange.
2026-04-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation of securities for the quarter ended March 31, 2026. It is addressed to stock exchanges and signed by the company secretary and the registrar & share transfer agent. The content is a compliance confirmation certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is short (3603 characters) and primarily serves as a regulatory compliance filing. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance certificate and not a financial report or announcement.
2026-04-06 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window pursuant to SEBI regulations related to insider trading. It mentions the upcoming declaration of audited financial results for the quarter and year ended March 31, 2026, but does not contain any financial data or results itself. The document is short (2312 characters) and serves as an announcement related to compliance and trading restrictions rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related notices that do not fit other specific categories.
2026-03-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.